A novel aerosol inhalation device for pressurized metered dose inhalation aerosols: Gammascintigraphic evaluation of pulmonary deposition profiles and comparison with commercial inhalation devices

1996 ◽  
Vol 128 (1-2) ◽  
pp. 55-63 ◽  
Author(s):  
N. Gaddipati ◽  
M. Graziosi ◽  
K. Ellway ◽  
M. Ganesan ◽  
H. Schreier
Keyword(s):  
Inhalation Device ◽  
Pulmonary Deposition ◽  
Inhalation Devices ◽  
Aerosol Inhalation ◽  
Metered Dose ◽  
Dose Inhalation

scholarly journals Comparison of pulmonary deposition of nebulized 99m technetium‐diethylenetriamine‐pentaacetic acid through 3 inhalation devices in healthy dogs

2021 ◽  
Vol 35 (2) ◽  
pp. 1080-1087
Author(s):  
Alejandra Carranza Valencia ◽  
Reinhard Hirt ◽  
Doris Kampner ◽  
Andreas Hiebl ◽  
Alexander Tichy ◽  
...  
Keyword(s):  
Pulmonary Deposition ◽  
Inhalation Devices ◽  
Healthy Dogs ◽  
Diethylenetriamine Pentaacetic Acid

scholarly journals A New Validated Stability Indicating RP-HPLC Method for Simultaneous Quantification of Formoterol Fumarate Dihydrate and Mometasone Furoate in Metered Dose Inhalation Aerosol

2021 ◽  
Vol 33 (11) ◽  
pp. 2723-2728
Author(s):  
Surya Prakash Mamillapalli ◽  
Gourabattina Lakshmi Prasanna ◽  
B. Venkata Subbaiah ◽  
N. Annapurna
Keyword(s):  
Flow Rate ◽  
Mobile Phase ◽  
Hplc Method ◽  
Mometasone Furoate ◽  
Simultaneous Estimation ◽  
Column Temperature ◽  
Stability Indicating ◽  
Metered Dose ◽  
Formoterol Fumarate ◽  
Dose Inhalation

Stability indicating reversed phase-HPLC method for simultaneous estimation of mometasone furoate (MAF) and formoterol fumarate (FFD) in metered dose inhalation aerosol (MDI) dosage formulation has been developed and discussed in the present work. The chromatographic separation was achieved using Hypersil ODS column (250 mm × 4.6 mm, 3 μm) using an isocratic separation mode at a flow rate of 1.2 mL/min, column temperature of 50 ºC. The system operates with a mobile phase comprising of solution-A (buffer): Solution-B (acetonitrile) mixed in the ratio of 70:30 %v/v at a UV detection wavelength of 214 nm. Retention times of mometasone furoate and formoterol fumarate found to be about 3 min and 7 min, respectively. All possible degradation products of both compounds were monitored at 214 nm and spectral purity along with % mass balance is assessed using PDA detector. Both analyte were subjected to force degradation studies, found all degradants were resolved from analyte peaks and also other process-related impurities. The proposed method is validated for specificity, linearity, accuracy, precision and robustness as per ICH guidelines and found to be adequate. Method stood to be robust with variation in column temperature, flow rate, pH of buffer and organic content in mobile phase.

scholarly journals Inhaled Drug Delivery: A Practical Guide to Prescribing Inhaler Devices

1998 ◽  
Vol 5 (3) ◽  
pp. 180-183 ◽  
Author(s):  
Pierre Ernst
Keyword(s):  
Drug Delivery ◽  
Inhaled Corticosteroids ◽  
High Ratio ◽  
Dose Inhaler ◽  
Breath Hold ◽  
Major Drawback ◽  
Inhalation Devices ◽  
Systemic Bioavailability ◽  
Metered Dose ◽  
Residual Capacity

Direct delivery of medication to the target organ results in a high ratio of local to systemic bioavailability and has made aerosol delivery of respiratory medication the route of choice for the treatment of obstructive lung diseases. The most commonly prescribed device is the pressurized metered dose inhaler (pMDI); its major drawback is the requirement that inspiration and actuation of the device be well coordinated. Other requirements for effective drug delivery include an optimal inspiratory flow, a full inspiration from functional residual capacity and a breath hold of at least 6 s. Available pMDIs are to be gradually phased out due to their use of atmospheric ozone-depleting chlorofluorocarbons (CFCs) as propellants. Newer pMDI devices using non-CFC propellants are available; preliminary experience suggests these devices greatly increase systemic bioavailability of inhaled corticosteroids. The newer multidose dry powder inhalation devices (DPIs) are breath actuated, thus facilitating coordination with inspiration, and contain fewer ingredients. Furthermore, drug delivery is adequate even at low inspired flows, making their use appropriate in almost all situations. Equivalence of dosing among different devices for inhaled corticosteroids will remain imprecise, requiring the physician to adjust the dose of medication to the lowest dose that provides adequate control of asthma. Asthma education will be needed to instruct patients on the effective use of the numerous inhalation devices available.

Sign in / Sign up

Export Citation Format

Share Document